Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland
Importance Biologics account for a substantial proportion of health care expenditures. Their
costs have been projected to reach US $452 billion in global spending by 2022. Given
recent expiration of patent protection of biologics, a shift toward greater follow-on
competition among biosimilars would be expected that would allow greater uptake and
lower drug costs. Objective To assess uptake and prices of biosimilars in the US compared
with 2 European countries (Germany and Switzerland) with national mechanisms for drug …
costs have been projected to reach US $452 billion in global spending by 2022. Given
recent expiration of patent protection of biologics, a shift toward greater follow-on
competition among biosimilars would be expected that would allow greater uptake and
lower drug costs. Objective To assess uptake and prices of biosimilars in the US compared
with 2 European countries (Germany and Switzerland) with national mechanisms for drug …
以上显示的是最相近的搜索结果。 查看全部搜索结果